Emerging pathogens have repeatedly determined the human history. In 2001, infectious diseases accounted for an estimated 26 % of deaths worldwide.

Or in other words, 1415 species of infectious organisms are known to be pathogenic to humans, 12 % were associated with diseases considered to be emerging. Nowadays, emerging diseases are connected with increase mortality; increase length of hospital stay and the burden on health care costs.

R-Biopharm has launched a group of new and unique RIDA^®QUICK tests for the rapid diagnosis of gastroenteritis. These rapid assays can be used to detect four emerging diseases causing gastroenteritis: Norovirus, Verotoxin/O157 Combi and Cryptosporidium/ Giardia/Entamoeba Combi, in human fecal samples. Especially the time-toresult and time-to-report is critical for highly contagious pathogens like viruses. Detection of Norovirus is of particular concern due to a rapid increase in its activity in Europe and the United States. Thus, a rapid diagnostic strategy combined with appropriate infection control measures can help duration and number of infected people. The results help to investigate and prevent Norovirus outbreaks. The new RIDA^®QUICK assays are quick and easy to perform. Sensitive and specific results are read visually in less then 20 minutes.

These patient-near tests are made not only for microbiology laboratories but are also suitable for nursing homes, because there is no need for special laboratory equipment.